Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996890 | 0.87 | IRAK4 (0.46) | IRAK4NTRK1RETPIM1PIM2 | |
| SCHEMBL18209075 | 0.82 | TGFBR1 (0.48) | TGFBR1HPGDHSD17B10KDM4EALDH1A1 | |
| SCHEMBL23518680 | 0.81 | PIM1 (0.42) | IRAK4RETPIM1PIM2PIM3 | |
| SCHEMBL21997023 | 0.80 | PIM1 (0.49) | TGFBR1IRAK4NTRK1HSD17B10KDM4E | |
| SCHEMBL23946217 | 0.80 | TGFBR1 (0.44) | TGFBR1NTRK1HPGDHSD17B10KDM4E | |
| SCHEMBL22188936 | 0.77 | CCNA2 (0.41) | TGFBR1IRAK4NTRK1HPGDHSD17B10 | |
| SCHEMBL10204204 | 0.76 | PDE2A (0.53) | TGFBR1IRAK4HPGDHSD17B10KDM4E | |
| SCHEMBL461752 | 0.75 | TGFBR1 (0.51) | TGFBR1HPGDHSD17B10KDM4EALDH1A1 | |
| SCHEMBL25162502 | 0.74 | TGFBR1 (0.50) | TGFBR1HPGDHSD17B10KDM4EALDH1A1 | |
| SCHEMBL22763214 | 0.74 | KDM4E (0.53) | TGFBR1HPGDHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885IRAK4 4/4885NTRK1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.